Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2017-09-05 20:41:38
Reporting Period:
Accepted Time:
2017-09-05 19:41:38
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1339970 Atyr Pharma Inc LIFE () 4
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1238362 John Mendlein 3545 John Hopkins Court, Suite 250
San Diego CA 92121
Ceo And Director Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-08-31 37,736 $2.65 367,883 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Warrant to Purchase Common Stock Acquisiton 2017-08-31 14,151 $0.00 14,151 $4.64
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
14,151 2017-08-31 2019-12-31 No 4 P Direct
  1. Represents shares acquired in a private placement pursuant to a Securities Purchase Agreement dated August 27, 2017 by and among the Company and a select group of institutional and accredited investors named therein (the "Securities Purchase Agreement"). Pursuant to the terms of the Securities Purchase Agreement, investors purchased common stock units for $2.65 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.375 shares of the Company's Common Stock.
  2. Includes 2,500 shares acquired under the Company's 2015 Employee Stock Purchase Plan (ESPP) on May 15, 2017.